Current studentsExisting staffContact us
 

Plasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease

Simple item page
dc.contributor.authorJones, G.
dc.contributor.authorvan Rij, A.
dc.contributor.authorCole, J.
dc.contributor.authorWilliams, M.
dc.contributor.authorBateman, E.
dc.contributor.authorMarcovina, S.
dc.contributor.authorDeng, M.
dc.contributor.authorMcCormick, S.
dc.date.issued2007
dc.description.abstractBackground: Increased lipoprotein(a) [Lp(a)] concentrations are predictive for coronary artery disease (CAD). The risk conferred by Lp(a) for other types of vascular disease compared with CAD has not been investigated within a single population. This study aimed to investigate Lp(a) risk association for 4 different types of vascular disease (including CAD) within a predominantly white population. Methods: We used an Lp(a) ELISA that measures Lp(a) independently of apo(a) size to measure plasma Lp(a) in patients [384 CAD, 262 peripheral vascular disease, 184 ischemic stroke (stroke), 425 abdominal aortic aneurysm] and 230 disease-free controls. We then conducted association studies with logistic regression, integrating the potential confounding effects of age, sex, diabetes, plasma lipids, and a history of previous hypertension, hypercholesterolemia, and smoking. Results: Multivariate analyses with Lp(a) concentrations of >45 nmol/L (the 75th percentile value for controls) as the clinical cutoff showed increased Lp(a) concentrations to be a risk factor for all disease groups, with adjusted odds ratios ranging from 1.96 [95% confidence interval (CI) 1.24-3.08] for CAD to 2.33 (95% CI 1.39-3.89) for PVD. The risk conferred by Lp(a) appeared to be independent of other confounders, including exposure to statin/fibrate therapies. Similar odds ratios and confidence intervals between disease groups indicated that increased Lp(a) conferred a similar risk for all groups studied. Conclusions: Lp(a) constitutes a stable risk factor of similar magnitude for 4 major forms of vascular disease. This association was not altered by exposure to standard lipid-lowering therapy.
dc.description.statementofresponsibilityGregory T. Jones, Andre M. van Rij, Jennifer Cole, Michael J.A. Williams, Emma H. Bateman, Santica M. Marcovina, Meiying Deng and Sally P.A. McCormick
dc.identifier.citationClinical Chemistry, 2007; 53(4):679-685
dc.identifier.doi10.1373/clinchem.2006.079947
dc.identifier.issn0009-9147
dc.identifier.issn1530-8561
dc.identifier.orcidBateman, E. [0000-0003-1665-102X]
dc.identifier.urihttp://hdl.handle.net/2440/62750
dc.language.isoen
dc.publisherAmer Assoc Clinical Chemistry
dc.rightsCopyright © 2007 by the American Association for Clinical Chemistry.
dc.source.urihttps://doi.org/10.1373/clinchem.2006.079947
dc.titlePlasma Lipoprotein(a) Indicates Risk for 4 Distinct Forms of Vascular Disease
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications